Projects

Tissue Regenix

The problem

There is a major clinical need for donor tissue in a number of surgical procedures, in order not
only to restore patient independence and mobility following injury, but also to save lives
(e.g. cardiovascular applications). In most cases, including orthopaedic and heart surgery, this
donor tissue is scarce and the ageing population is causing a significant increase in demand.

The Technology
Researchers in the Institute of Medical and Biological Engineering at the University of Leeds have
developed novel technologies to produce acellular tissue matrices.

The matrices have:

  • excellent biocompatibility
  • immunocompatibility
  • resistance to calcification
  • shown rapid and successful regeneration in vivo and the same biomechanical properties as the native tissue to be replaced

The Partners:

  • University of Leeds
  • Tissue Regenix Ltd
  • IP Group
  • White Rose University Consortium

 

Aims:
Tissue Regenix was established in May 2006 as spin-out from the University of Leeds to exploit innovative platform technologies in the field of tissue engineering and regenerative medicine. By using the Tissue Regenix tissue treatment processes, the company aims to provide products that can be used to replace or repair native tissue with a tissue of equivalent nature. The company is initially concentrating on developing products to address important clinical needs in cardiovascular and orthopaedic surgery, and is aiming at delivery to patients in the clinic within 2-5 years.


Benefits of the Collaboration:
By combining the world-class research and expertise of the University of Leeds and their focus on clinical translation, Tissue Regenix were set up with early stage funding from IP Group. The strong links between research and translation have helped to secure a further £685,000 in equity finance from IP Group and the White Rose Technology Seedcorn Fund.